
GOSS Stock Forecast & Price Target
GOSS Analyst Ratings
Bulls say
Gossamer Bio is a clinical-stage biopharmaceutical company with a positive outlook due to its expanding pipeline of promising products addressing unmet needs in immunology, inflammation, and oncology, as well as recent financial actions aimed at reducing debt and extending maturity. With a strong clinical framework and management's confidence in data durability and safety, analysts anticipate positive results for seralutinib in pulmonary arterial hypertension, contributing to a projected price target of $10 per share.
Bears say
Gossamer Bio is facing several challenges that could significantly impact its future prospects. These include potential delays in obtaining regulatory approval for its pipeline products, specifically Seralutinib, due to potential requirements for additional data or longer studies. The company is also facing financial struggles, as evidenced by its recent exchange offer to address its convertible debt due in 2027 and its need for additional financing to support commercial launch. Furthermore, their flagship product, Seralutinib, may have limited addressable market opportunities, and its current data may not meet investor expectations. These factors lead to a negative outlook on Gossamer Bio's stock, with a significant decrease in its target price to $1/share and a downgrade to a Neutral rating.
This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GOSS Analyst Forecast & Price Prediction
Start investing in GOSS
Order type
Buy in
Order amount
Est. shares
0 shares